A new approach to the treatment of osteoporosis.
Osteoporosis remains a significant clinical problem despite the availability of effective therapies. The main therapy still needed is an anabolic agent for the treatment of osteoporosis. This study examined the in vivo effect of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin, which controls the first step in the biosynthesis of cholesterol, on bone formation in rats. Histologic specimens were collected 7, 14, and 21 days after administration of 1 mg of simvastatin for 5 days and compared with control specimens for changes in bone tissue. The observed effects on the bone in a healthy animal model included advancement of the blood supply, acceleration of the proliferation and differentiation of osteoprogenitor cells, and formation of osteoid tissue.
Erdemli
Bülent
B
Department of Orthopedics, Ankara University, Faculty of Medicine, Ankara, Turkey.
Serin-Kiliçoglu
Sibel
S
Erdemli
Esra
E
D000818:Animals; D001846:Bone Development / Q000187:drug effects*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D010024:Osteoporosis / Q000188:drug therapy*; D051381:Rats; D019821:Simvastatin / Q000494:pharmacology*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin